

**VIVALIS GRANTS RIGHTS TO EBx<sup>®</sup> CELL LINE  
FOR TESTING IN PRODUCTION OF VIRAL VACCINES**

**Nantes (France) – June 18<sup>th</sup>, 2008**

VIVALIS announced today that it has signed a research license with an animal health company (undisclosed), to evaluate EBx<sup>®</sup> cell line (EB66) for the production of several viral vaccines.

The world-wide veterinary vaccine market was 1.5 billion USD in 2007. VIVALIS has already licensed its EBx<sup>®</sup> platform to major actors in the field including: MERIAL, INTERVET-SCHERING PLOUGH, FORT DODGE (WYETH), VIRBAC, KAKETSUKEN.

Franck GRIMAUD, VIVALIS CEO, declares: *“VIVALIS is very pleased to enter in this agreement that should help support our new licensee’s R&D efforts for the development of animal vaccines. This new license confirms again that the EBx<sup>®</sup> cell platform is a reference cell substrate for the industrial manufacture of viral vaccines. We are strongly convinced that an increasing number of vaccine companies will move away from chicken eggs and adopt the EBx<sup>®</sup> cell platform as their standard production platform in a foreseeable future”.*

Terms of the agreement were not disclosed.

\*\*\*\*\*

**Next press release:**

**13 August 2008, after closure of the Euronext Paris market: Turnover for the 2nd quarter of 2008**

**About VIVALIS (www.vivalis.com)**

VIVALIS (NYSE- Euronext: VLS) is a biopharmaceutical company that provides innovative cell-based solutions to the pharmaceutical industry for the manufacture of vaccines and proteins, and develops drugs for the prevention and treatment of viral diseases. VIVALIS’s expertise and intellectual property are exploited in three main areas:

1. The development and manufacturing of vaccines. VIVALIS offers research and commercial licenses for its EBx<sup>®</sup> embryonic stem cell lines to pharmaceutical and biotechnology companies for the production of viral vaccines.
2. The development of production systems for recombinant proteins and monoclonal antibodies. VIVALIS licenses its EBx<sup>®</sup> embryonic stem cell lines for the production of recombinant proteins to biotechnology and pharmaceutical companies.
3. The construction of a portfolio of proprietary products in the area of vaccines and anti-viral molecules (hepatitis C).

Based in Nantes (France), VIVALIS was founded in 1999 by the Grimaud group (1,450 employees), the second largest group worldwide in animal genetic selection. VIVALIS has established numerous partnerships with world leaders in this sector, including Sanofi Pasteur, GlaxoSmithKline, Novartis Vaccines, Kaketsuken, Merial and SAFC Biosciences. VIVALIS is a member of the French<sub>1/2</sub>

ATLANTIC BIOTHERAPIES cluster of competitive excellence.

**Euronext Paris Compartment C - FR0004056851**  
Reuters: **VLS.PA** – Bloomberg: **VLS FP**

**Investor relations:**

**VIVALIS**

Franck Grimaud, C.E.O.

Email: [investors@vivalis.com](mailto:investors@vivalis.com)

***NewCap***

Financial Communication Agency

Steve Grobet / Emmanuel Huynh

Tel.: +33 (0) 1 44 71 94 91

***Email:*** [vivalis@newcap.fr](mailto:vivalis@newcap.fr)